Computational Design of CYP102A1 Variants for Biosynthesis of a Next-Generation Antiplatelet Drug DT-678
ACS Synthetic Biology · 20.03.2026 · 15 (3) · 1082-1089
DOI: 10.1021/acssynbio.5c00768 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, online erschienen am 06.03.2026. Verfasst von Yudong Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, The University of Michigan, Ann Arbor, Michigan 48109 United States. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Platelet Aggregation Inhibitors, NADPH-Ferrihemoprotein Reductase, Bacterial Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Clopidogrel is a widely used antiplatelet prodrug to treat acute coronary syndromes. However, its clinical efficacy is hampered by ineffective bioactivation to produce the pharmacologically active metabolite (AM), leading to variability in the antiplatelet response among different ethnic groups. To overcome the shortcomings of clopidogrel, DT-678 was developed by conjugating AM to 3-nitropyridine-2-thiol via a mixed disulfide bond. It has been challenging to produce the conjugate in a high yield by chemical synthesis. Here, we report the first de novo biosynthesis of DT-678 using engineered CYP102A1 variants. We applied structure-based computational design using UniDesign to generate three variants (UD4, UD5, and UD6) that enhanced the catalytic activity and selectivity toward DT-678 synthesis. Among them, UD6 demonstrated the highest total turnover number and DT-678-specific productivity under the optimized conditions. Mechanistic analysis revealed that rapid enzyme inactivation, driven by reactive oxygen species (ROS) such as superoxide and hydrogen peroxide, limited the overall yield. Remarkably, we found that ascorbic acid significantly protected CYP102A1 variants from inactivation and, hence, increased production yield. This work establishes a scalable enzymatic strategy for DT-678 biosynthesis and highlights the importance of combining protein engineering with redox control to overcome limitations in CYP-catalyzed reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, The University of Michigan, Ann Arbor, Michigan 48109 United States.
- Department of Internal Medicine, The University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Xiaoqiang Huang, Yoichi Osawa, Haoming Zhang
Förderung
- NHLBI NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- National Institute of Environmental Health Sciences
- National Heart, Lung, and Blood Institute
- Medical School, University of Michigan
- National Institute of General Medical Sciences
Zitieren
APA
Sun, Y., Huang, X., Zhang, J., Osawa, Y., Chen, Y. E., & Zhang, H. (2026). Computational Design of CYP102A1 Variants for Biosynthesis of a Next-Generation Antiplatelet Drug DT-678. ACS Synthetic Biology, 15(3), 1082-1089. https://doi.org/10.1021/acssynbio.5c00768
Vancouver
Sun Y, Huang X, Zhang J, Osawa Y, Chen YE, Zhang H. Computational Design of CYP102A1 Variants for Biosynthesis of a Next-Generation Antiplatelet Drug DT-678. ACS Synthetic Biology. 2026;15(3):1082-1089. doi:10.1021/acssynbio.5c00768
BibTeX
@article{Sun2026,
author = {Sun, Yudong and Huang, Xiaoqiang and Zhang, Jifeng and Osawa, Yoichi and Chen, Y Eugene and Zhang, Haoming},
title = {Computational Design of CYP102A1 Variants for Biosynthesis of a Next-Generation Antiplatelet Drug DT-678},
journal = {ACS Synthetic Biology},
year = {2026},
volume = {15},
number = {3},
pages = {1082--1089},
doi = {10.1021/acssynbio.5c00768}
}
EUVIMED